Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Melanoma 236Carcinoma, Non-Small-Cell Lung 78Carcinoma, Renal Cell 61Neoplasm Metastasis 52Neoplasms 47Prostatic Neoplasms 34Uveal Melanoma 29Lung Neoplasms 28Pancreatic Neoplasms 27Carcinoma, Hepatocellular 25Brain Neoplasms 23Sarcoma 22Colorectal Neoplasms 21Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 18Small Cell Lung Carcinoma 18Skin Neoplasms 17Kidney Neoplasms 17Diabetes Mellitus, Insulin-Dependent, 12 17Carcinoma, Transitional Cell 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 14Urinary Bladder Neoplasms 13Mesothelioma 13Uterine Cervical Neoplasms 12Recurrence 12Glioblastoma 12Multiple Myeloma 11Lymphoma 11Clear-cell metastatic renal cell carcinoma 11

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 8Bevacizumab 8toripalimab 7senaparib 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Gemcitabine 5Fluorouracil 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorodeoxyglucose F18 4spartalizumab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3Midazolam 3Itraconazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Solid Tumor × Ipilimumab × Clear all
NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Recruiting
542 enrolled
Other solid neoplasm

Solid Tumor

NCT03195478 2025-09-15

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
37 enrolled 32 charts
Other solid neoplasm

Solid Tumor

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn
Other solid neoplasm

Solid Tumor

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Idera Pharmaceuticals, Inc.

Phase 2 Active not recruiting
30 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡